UK healthtech startup Stride raises £4.6M to expand preventative health platform

Preventative health platform Stride secured £4.6 million in seed funding to enhance its diagnostics-driven services and expand globally. The investment round includes backing from Arāya Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Better Ventures, Innovate UK, and a16z Scout Fund investors, alongside numerous angel investors.

Stride, founded by Olympic medallist and DNAfit co-founder Andrew Steele, provides a membership that integrates DNA, blood, and gut health testing with personalized insights. The platform empowers individuals to comprehend their health data, monitor progress over time, and make informed decisions about their well-being. By shifting focus from reactive health treatment to early risk identification and intervention, Stride aims to make preventative health more accessible and promote lasting lifestyle changes.

Founder Steele believes that engaging and accessible preventative health measures could transform how people manage their health, potentially reshaping longevity and overall health. To achieve this, Stride has secured Innovate UK funding for two research projects: one on a multiomic approach to biological age and another on an AI-powered health copilot.

This copilot will analyze laboratory test results, wearable data, health records, and other information to provide personalized insights. The startup is also partnering with Triple Bond at The BoTree Hotel and LongLane, a biohacking destination, to offer customized experiences using Stride's diagnostic testing. The new funding will help Stride develop a predictive and personalized health platform, targeting international expansion outside the UK by the end of 2026.